Company intelligence / Profile preview

Generation Bio

Cambridge, Massachusetts, United Statesgenerationbio.com ↗

Ownership: Public · GBIO
Development stage: Other

Overview

Generation Bio has developed a T cell-selective lipid nanoparticle that achieved approximately 98% knockdown of the B2M protein in human T cells in both in vitro and mouse studies. The company plans to announce its lead target and indication in mid-2025 and submit an IND application in the second half of 2026.[6]

Therapeutic areas: Immunology
Modalities: siRNA therapeuticsgenetic medicines
Industry: Biotech

Beyond the preview

Go deeper on Generation Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Generation Bio.